Braveheart, a biotech company backed by a16z, is seeking to raise $318.8 million through a U.S. IPO
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise up to $318.8 million through an initial public offering (IPO). This move will make it part of the growing wave of biotech companies going public.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Samsung Electronics fell 5.99% from its previous close, now trading at ₩227,500.
-
2
Samsung Electronics is down 4.44% from its previous close, now trading at ₩231,250.
-
3
Cryptocurrency Investing for Beginners: A Guide to Buying and Asset Management
-
4
Former Aptos advisor "Buzz" leaves project, shifts meme marketing efforts to Meta stock
-
5
WOL Token: Current Status and Investment Considerations for World of Legends
-
6
Nikkei Asia: Iranian separatists intensify attacks and seize territory in response to a potential full-scale US assault.
-
7
The Federal Reserve maintained interest rates, with a 10-2 vote. Lisa Cook and Beth Hammack voted in favor of a rate hike.
-
8
FOR Token (ForTube) Issuance Price and Project Analysis
-
9
President Trump returns to Ohio, highlighting over $100 billion in private investment attracted to the state during his term.
-
10
A Boston office building was sold at a foreclosure auction for one-third of its 2019 price, representing a discount of approximately $546 million.
Markets Today
Recommended Reading



